158 related articles for article (PubMed ID: 33459177)
1. Molecular mechanism study of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Wu X; Guo Q; Li Q; Wan S; Li Z; Zhang J
J Biomol Struct Dyn; 2022 Aug; 40(13):5848-5857. PubMed ID: 33459177
[TBL] [Abstract][Full Text] [Related]
2. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
3. Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Wan S; Yan R; Jiang Y; Li Z; Zhang J; Wu X
J Biomol Struct Dyn; 2019 Oct; 37(16):4384-4394. PubMed ID: 30499387
[TBL] [Abstract][Full Text] [Related]
4.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
5. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
To C; Beyett TS; Jang J; Feng WW; Bahcall M; Haikala HM; Shin BH; Heppner DE; Rana JK; Leeper BA; Soroko KM; Poitras MJ; Gokhale PC; Kobayashi Y; Wahid K; Kurppa KJ; Gero TW; Cameron MD; Ogino A; Mushajiang M; Xu C; Zhang Y; Scott DA; Eck MJ; Gray NS; Jänne PA
Nat Cancer; 2022 Apr; 3(4):402-417. PubMed ID: 35422503
[TBL] [Abstract][Full Text] [Related]
6. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.
To C; Jang J; Chen T; Park E; Mushajiang M; De Clercq DJH; Xu M; Wang S; Cameron MD; Heppner DE; Shin BH; Gero TW; Yang A; Dahlberg SE; Wong KK; Eck MJ; Gray NS; Jänne PA
Cancer Discov; 2019 Jul; 9(7):926-943. PubMed ID: 31092401
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
[TBL] [Abstract][Full Text] [Related]
8. Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor.
Li M; Xu Y; Guo J
Chem Biol Drug Des; 2022 Apr; 99(4):650-661. PubMed ID: 35152550
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
10. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations.
Li M; Guo J
ACS Chem Neurosci; 2021 Feb; 12(3):462-472. PubMed ID: 33435671
[TBL] [Abstract][Full Text] [Related]
12. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
[TBL] [Abstract][Full Text] [Related]
13. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
14. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Wang DD; Ma L; Wong MP; Lee VH; Yan H
PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.
Dou D; Wang J; Qiao Y; Wumaier G; Sha W; Li W; Mei W; Yang T; Zhang C; He H; Wang C; Chu L; Sun B; Su R; Ma X; Gong M; Xie L; Jiang W; Diao Y; Zhu L; Zhao Z; Chen Z; Xu Y; Li S; Li H
Eur J Med Chem; 2022 Dec; 244():114856. PubMed ID: 36279692
[TBL] [Abstract][Full Text] [Related]
16. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
17. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Wang S; Tsui ST; Liu C; Song Y; Liu D
J Hematol Oncol; 2016 Jul; 9(1):59. PubMed ID: 27448564
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC).
Karnik KS; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Wakte PS
J Biomol Struct Dyn; 2023 Jul; 41(10):4696-4710. PubMed ID: 35532095
[TBL] [Abstract][Full Text] [Related]
19. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]